[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Sarah R Verhoeff, Sjoukje F Oosting, Sjoerd G Elias, Suzanne C van Es, Sophie L Gerritse, Lindsay Angus, Sandra Heskamp, Ingrid M E Desar, C Willemien Menke-van der Houven van Oordt, Astrid A M van der Veldt, Anne I J Arens, Adrienne H Brouwers, Bertha Eisses, Peter F A Mulders, Otto S Hoekstra, Gerben J C Zwezerijnen, Winette T A van der Graaf, Erik H J G Aarntzen, Wim J G Oyen, Carla M L van Herpen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
17 Downloads (Pure)

Fingerprint

Dive into the research topics of '[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science